Commentary on: The relationship between heparin level and activated clotting time in the adult cardiac surgery population

FitzGerald, D.
March 2009
Perfusion;Mar2009, Vol. 24 Issue 2, p97
Academic Journal
Information about the issues discussed at the 30th Annual Seminar of the American Academy of Cardiovascular Perfusion held in Dallas, Texas from February 5-8, 2009 is presented. Topics include the relationship of heparin level and activated clotting time in the adult cardiac surgery populace. The event featured several speakers including John Toomasian, Eric Jenkins and Daniel Fitzgerald.


Related Articles

  • The relationship between heparin level and activated clotting time in the adult cardiac surgery population. FitzGerald, D. J.; Patel, A.; Body, S. C.; Garvin, S. // Perfusion;Mar2009, Vol. 24 Issue 2, p93 

    The purpose of this descriptive study was to examine the relationship between heparin levels (HL) determined by heparin protamine titration (HPT) and activated clotting time (ACT) for cardiopulmonary bypass (CPB) in an adult cardiac surgery population. We examined institutional databases for all...

  • Comparison of ACT point-of-care measurements: repeatability and agreement. Bosch, Y. P. J.; Ganushchak, Y. M.; de Jong, D. S. // Perfusion;Jan2006, Vol. 21 Issue 1, p27 

    Background: Accurate control of heparin anticoagulation is necessary during all stages of cardiopulmonary bypass (CPB). The activated clotting time, first described by Hattersley in 1966, is mostly used for determination of anticoagulation. Either celite or kaolin are used as activators. An ACT...

  • A statistical analysis of factors predisposing patients to heparin resistance. Tanee Chan; Nian Chih Hwang; Chong Hee Lim // Perfusion;Mar2006, Vol. 21 Issue 2, p99 

    Heparin resistance (HR) is occasionally encountered in cardiac surgery. The objective of this study is to identify possible factors predisposing patients to heparin resistance. Four hundred patients scheduled for elective cardiac surgery requiring the use of cardiopulmonary bypass (CPB) were...


    An abstract of the article "In Vitro Effects of Low Molecular Weight Heparin on Clot Rate" by Shi Xu-bo and colleagues is presented.

  • KardiohirurÅ¡ka procedúra kod bolesnika sa heparinom indukovanom trombocitopenijom (HIT II). Jović, M. D.; Nežić, D. G.; Čalija, B. M.; Nenadić, D. S.; Knežević, A. M.; Borzanović, M. D.; Krivokapić, B. M.; Petrović, I. M.; Djukanović, B. P. // Acta Chirurgica Iugoslavica;2009, Vol. 56 Issue 1, p47 

    Heparin-induced thrombocytopenia (HIT) might be life-threatening in patients undergoing open heart surgery, due to thromboembolic events, thrombocytopenia and bleeding. If cardiac surgery with cardiopulmonary bypass (CPB) is necessary, anticoagulation therapy will he based on usage of danaparoid...

  • Differential Effects of Unfractionated Heparin and Low-Molecular-Weight Heparins on Tissue Thromboplastin Inhibition Test. Gerbutavicius, Rolandas; Iqbal, Omer; Messmore, Harry; Hoppensteadt, Debra A.; Demir, Muzaffer; Khan, Erum; Bacher, Peter; Fareed, Jawed // Clinical & Applied Thrombosis/Hemostasis;Oct2000, Vol. 6 Issue 4, p190 

    Circulating anticoagulants are endogenously produced substances that interfere with in vitro tests of coagulation like activated partial thromboplastin time (APTT). and cause prolongation of the clotting times. Evaluation of the abnormal APTT involving various factor assays and mixing studies...

  • aPTT in Heparinized Patients: Influence of the Interval Between Sampling and Testing. Rachakonda, Vikrant; Rachakonda, Leelanand; Belliveau, Robert R. // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p213 

    Activated partial thromboplastin times(aPTTs) from, 29 whole blood samples were drawn from patients receiving unfractionated heparin through a constant intravenous drip. Three aPTTs were determined for each whole blood sample. The first aPTT was performed on a separate portion of the original...

  • Perioperative Low-Molecular-Weight Heparin and Neuraxial Anesthesia: A Review of Current Practice Guidelines. Cannavo, Dominick; Friedman, Richard J. // Internet Journal of Anesthesiology;2003, Vol. 6 Issue 2, p57 

    Over the past nine years, the wide acceptance of low-molecular-weight heparins (LMWHs) in the United States has been the result of this class of drugs excellent safety and efficacy profile across multiple applications to prevent and treat arterial and venous thromboembolic disease. There has...

  • Hemorrhagic Complications in Patients Treated with Anticoagulant Doses of a Low Molecular Weight Heparin (Enoxaparin) in Routine Hospital Practice. Ellis, Martin H.; Hadari, Ruth; Tchuvrero, Noa; Shapira, Shirley; Kovlenko, Irena; Kozmìakova, Mariana; Zissin, Rivka; Elis, Avishay // Clinical & Applied Thrombosis/Hemostasis;Apr2006, Vol. 12 Issue 2, p199 

    Low molecular weight heparins (LMWHs) are a rapidly growing class of anticoagulant drug. Their efficacy has been demonstrated in several clinical settings where they are rapidly becoming the anticoagulant of choice. Controlled clinical studies in patients with deep vein thrombosis, pulmonary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics